nmtr-20210323

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 23, 2021

9 Meters Biopharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-37797

27-3948465

(State or other jurisdiction of
incorporation or organization)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

8480 Honeycutt Road, Suite 120, Raleigh, NC 27615

(Address of principal executive offices) (Zip Code)

(919) 275-1933

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock $0.0001 Par Value	NMTR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒


Item 8.01.			Other Events.

On March 23, 2021, 9 Meters Biopharma, Inc. (the “Company”) updated its corporate presentation which can also be found on the Company’s website at www.9meters.com under the section titled Investors. A copy of the Company’s presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

In addition, as previously announced on February 1, 2021, the Company will host a research and development webinar on its’ short bowel syndrome program and the results of the recently completed Phase 1b/2a clinical trial on Tuesday, March 23, 2021 at 11:00 AM Eastern Time. A copy of the presentation to be used during the webinar is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.


Item 9.01.			Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.			Description
Exhibit 99.1			9 Meters Biopharma, Inc. Corporate Presentation
Exhibit 99.2			9 Meters Biopharma, Inc. R&D Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	9 Meters Biopharma, Inc.

Date: March 23, 2021	By:	/s/ Edward J. Sitar
		Edward J. Sitar
		Chief Financial Officer

SEC Form 8-K filed by 9 Meters Biopharma, Inc.